AstraZeneca on Friday said its Imfinzi drug in combination with the Imjudo antibody and platinum-based chemotherapy has been approved in the US for the treatment of adult patients with stage IV non-small cell lung cancer.
The approval by the Food and Drug Administration (FDA) was based on the results from the Poseidon Phase 3 trial.
Patients treated with a limited course of five cycles of Imjudo added to Imfinzi plus four cycles of platinum-based chemotherapy experienced a 23% reduction in the risk of death versus a range of chemotherapy options.
Reporting by Frank Prenesti for Sharecast.com
